The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced an exponential growth.
The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII)
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Josep Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.
We are looking for a Predoctoral Researcher for the 3D chromatin organization group led by Dr. Biola M. Javierre
RESEARCH DESCRIPTION
We are a group of passionate scientists with an insatiable thirst for learning about spatio-temporal organization of the DNA. Our group combines cutting-edge experimental and bioinformatics approaches to understand the specific 3D chromatin organization of haematopoietic cells and its alteration in blood cancers. Our long-term goal is to keep taking steps forwards in the fight against cancer. We will be unstoppable until we cure it.
MAIN RESPONSABILITIES
The candidate will investigate the role of distal regulatory elements in haematopoiesis and immune cell maturation throughout ontogeny, as well as the consequences of their dysregulation in hematological malignancies and immune related diseaes.
WHAT WE NEED
• Master’s degree in Bioinformatics, Biomedical Sciences or a related discipline.
• Strong expertise in computational biology.
• Strong interest and motivation to pursue a research career in the biomedical field.
• Excellent academic performance.
• Proven ability to work both independently and as part of a team.
• Proactive attitude, creativity, and a collaborative mindset.
• Capacity to manage multiple tasks and adapt to varying workloads.
• Strong interpersonal and communication skills.
• Fluency in English, both written and spoken.
WHAT WE OFFER
• Full time contract of 39 hours per week
• Temporary contract (“Indefinido por actividades científico técnicas”) Este contrato es parte del proyecto PR_EX_2024-02 financiado por CRIS Contra el Cáncer.
• Measures to reconcile work and family life (flexible work schedule, 23 working days of vacation and days for personal matters).
• Flexible remuneration program (kindergarten and other measures).
• An exciting and innovative research project.
• Working in the mixed basic and clinical research environment of the Josep Carreras Leukaemia Research Institute.
• Incorporation in a multinational and highly collaborative team.
• The stimulating environment of the Barcelona metropolitan area.
DEADLINE
Please submit your application by July 14th, 2026.
WHO WE ARE?
The mission of the Josep Carreras Leukaemia Research Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer, with a special emphasis on Leukaemia and other malignant blood diseases, with the aim of finding a cure for these diseases.
The IJC’s vision is to be a world-class reference and excellent research center that contributes to the improvement of results, and the cure of patients affected by leukaemia and other malignant haemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.
In 2019, IJC was honored with the “Human Resources Excellence in Research Award” by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers. The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC’s commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The Board of Trustees is composed of representatives of the Generalitat de Catalunya (regional government), University of Barcelona, Autonomous University of Barcelona, the City of Badalona and the Jose Carreras International Leukaemia Foundation
The Catalan government provides hard money on an annual basis. The Jose Carreras International Leukaemia Foundation provides start-up funds, project funds as well as financial support for investments.
The JCI has an international scientific advisory board served by prominent researchers from US and Europe.
The IJC has been awarded ERC and other EU grants.
The IJC is an equal-opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.
The Josep Carreras Leukaemia Research Institute was founded in 2010, by the Josep Carreras Foundation and the Government of Catalonia, as the first European research centre devoted exclusively to leukaemia and other malignant blood diseases, and one of the few that exist in the world.
We investigate basic, epidemiological, preventive, clinical, and translational aspects of leukaemia and other hematologic malignancies.
Our research aims to identify new therapeutic targets and enable us to develop more precise and less aggressive treatments. We aspire to understand the origin and development of leukaemias and other malignant haematological pathologies, to be able to prevent them.
We work for a future in which all leukaemias will be curable. Our fight will endure until there's a cure.
